Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors

American Journal of Managed Care

Volumn 13, Issue SUPPL. 10, 2007, Pages

  Davidson, Michael H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CLOPIDOGREL; COLESEVELAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; WARFARIN;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COST OF ILLNESS; DIAGNOSTIC IMAGING; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; MONEY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHARMACIST; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID ARTERY, INTERNAL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; RISK FACTORS; TUNICA INTIMA;

EID: 37849026709     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Affairs. 2007;26:38-48.
2. Turpie AGG. Burden of disease: medical and economic impact of acute coronary syndromes. Am J Manag Care. 2006;12(16 suppl):S430-S434.
3. Brown DL, Boden-Albala B, Langa KM, et al. Projected costs of ischemic stroke in the United States. Neurology. 2006;67:1390-1395.
4. Caro JJ, O'Brien JA, Hollenbeak CS, et al. Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles. Value Health. 2007;(10 suppl 1):S12-S20.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol. 2006;47:2130-2139.
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
8. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
9. Fox KM, Gandhi SK, Blasetto JW, et al. Dyslipidemia treatment patterns and low-density lipoprotein cholesterol monitoring and management of patients with atherosclerosis in real-world clinical practice. Presented at: the American Heart Association Quality of Care and Outcomes Research in Cardiovascular disease and Stroke meeting; May 9-11, 2007; Washington, DC. [Abstract: Circulation. May 29, 2007:e572.]
10. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis. 1999;10(suppl 1):S9-S12.
11. Crouse JR, Grobbee DE, O'Leary DH, et al. Measuring effects on intima media thickness: an evaluation of rosuvastatin in subclinical atherosclerosis - the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther. 2004;18:231-238.
12. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-1207.
13. Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110:265-270.
14. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med. 2001;134:224-238.
15. Ohashi R, Mu H, Yao Q, et al. Atherosclerosis: immunopathogenesis and immunotherapy. Med Sci Monit. 2004;10:RA255-RA260.
16. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
17. Ben-Haim S, Israel O. PET/CT for atherosclerotic plaque imaging. QJ Nucl Med Mol Imaging. 2006;50:53-60.
18. Van Mieghem CAG, McFadden EP, de Feyter PJ, et al. Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities. The Integrated Biomarker and Imaging Study. J Am Coll Cardiol. 2006;47:1134-1142.
19. Weissberg PL. Atherogenesis: current understanding of the causes of atheroma. Heart. 2000;83:247-252.
20. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.
21. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL-C, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
22. Fonarow GC. Treating to goal: new strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis. Vasc Med. 2002;7:187-194.
23. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565.
24. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243-2250.
25. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83:361-366.
26. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.
27. Sipahi I, Tuzcu EM, Schoenhagen P, et al. Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. Atherosclerosis. 2006;189:229-235.
28. Taylor A, Shaw LJ, Fayad Z, et al. Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis. 2005;180:1-10.
29. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-467.
30. Nicholls SJ, Sipahi I. Emerging role of intravascular ultrasound in the assessment of experimental anti-atherosclerotic therapies. Curr Med Chem. 2006;13:1727-1734.
31. Nicholls SJ, Chhatriwalla AK, Lundman P. Impact of statins on atherosclerotic plaque. Future Cardiol. 2007;3:157-164.
32. Crouse JR, Grobbee DE, O'Leary DH, et al. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. Curr Med Res Opin. 2007;23:641-648.
33. Wattanakit K, Folsom AR, Chambless LE, et al. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2005;149:606-612.
34. Villines TC, Taylor AJ. Non-invasive atherosclerosis imaging: use to assess response to novel or combination lipid therapies. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:557-564.
35. Salam AM. Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. Expert Opin Investig Drugs. 2004;13:707-713.
36. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
37. Treatment guidelines: drugs for lipids. Treat Guidel Med Lett. 2005;3:15-22.
38. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160.
39. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268-275.
40. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk. 2001;8:383-390.
41. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144:1044-1051.
42. Schuster H. Improving lipid management - to titrate, combine or switch. Int J Clin Pract. 2004;58:689-694.
43. Shepherd J, Hunninghake DB, Barter P, et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol. 2003;91(suppl 5A):11C-19C.
44. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006;7:35.
45. Manufacturer product information. Physicians' Desk Reference. 60th ed. Montvale: NJ: Thomson Healthcare; 2006. Information retrieved for lovastatin (Mevacor), lovastatin extended-release (Altoprev), fluvastatin (Lescol, Lescol XL), pravastatin (Pravachol).
46. Crouse JR, Lukacsko P, Niecestro R, et al. Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. Am J Cardiol. 2002;89:226-229.
47. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol. 1993;71:810-815.
48. Lukacsko P, Walters EJ, Cullen EI, et al. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia. Curr Med Res Opin. 2004;20:13-18.
49. Davidson MH, Palmisano J, Wilson H, et al. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther. 2003;25:2738-2753.
50. Olsson AG, Pauciullo P, Soska V, et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther. 2001;23:45-61.
51. Isaacsohn JL, LaSalle J, Chao G, et al. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. Clin Ther. 2003;25:904-918.
52. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055-2060.
53. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR trial. JAMA. 2007;297:1344-1353.
54. Evans GW, Raichlen JS, Bots ML, et al; on behalf of the METEOR Study Group. Rosuvastatin treatment in carotid atherosclerosis: effect of Framingham risk factors and baseline intima-media thickness in the METEOR trial. Circulation. 2007;116(suppl II):848. Abstract 3730.
55. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
56. Nissen SE. Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Med. 2005;118(suppl 12A):22S-27S.
57. Shepherd J. Special report: highlights of the 75th European Atherosclerosis Society congress. Atherosclerosis. 2005;181:S1-S7.
58. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005;46:106-112.
59. Killilea T, Funk L. Cost efficiency and formulary considerations for statin therapy. Am J Manag Care. 2006;12(suppl):S325-S331.